Published On: Fri, Jul 15th, 2011

Wacker to showcase liquid silicon rubber for food dosing valves at Fakuma

wacker1a_20110714_cprjWacker Chemie AG, a global provider of specialty chemicals, announced on July 12 that it will

showcase the Elastosil LR 3066 product range among other products at the 2011 Fakuma international trade show for plastics processing that will take place from October 18-22 in Germany.

The Elastosil LR 3066 line’s special properties are the result of a new formulation concept that prevents neighboring silicone surfaces from reacting with each other irreversibly during subsequent heat treatment. In addition to friction reduction, this effect has a particularly positive impact on the manufacture of silicone moldings with specified slit-shaped openings. For example, dosing-valve slits made of Elastosil LR 3066 do not heal during post-curing, said Wacker.

In contrast to conventional standard silicones, such valve slits can be produced prior to post-curing without the use of additives to separate the slit edges. This simplifies the manufacturing process and helps prevent the additive-related risk of contamination, the company stated. The non-healing effect can be exemplified by the production of dosing valves for ketchup or mayonnaise bottles.

Furthermore, the formulation concept imparts the cured rubber with an intrinsically smooth surface, as is already widely known for other silicone products of the Elastosil LR 3065 line for technical applications. Compared to standard silicones, the 50-70% lower friction coefficient can be an advantage during assembly of the components since friction can hinder silicone-part installation. Lower friction also facilitates release after injection molding.

The Elastosil LR 3066 product range comprises three types that cure to the hardnesses of 40, 60 and 80 Shore A. These three liquid silicone rubber types are transparent and can be pigmented in any color. The cured rubber complies with the food standards of the Federal German Institute for Risk Assessment (BfR), the French Arrêté du 25 novembre 1992 and the US Food and Drug Administration (FDA).


Source :